Journal
ACADEMIC EMERGENCY MEDICINE
Volume 21, Issue 6, Pages 659-666Publisher
WILEY-BLACKWELL
DOI: 10.1111/acem.12390
Keywords
-
Categories
Funding
- PDLBiopharma
- National Center for Research Resources (NCRR)
- National Center for Advancing Translational Sciences (NCATS)
- National Institutes of Health (NIH) [KL2 RR025740-05]
- Abbott
- Alere
- NIH/NHLBI
- Medtronic
- Cardiorentis
- Abbott Point-of-Care
- Novartis
- Medicines Company
- Astellas Consulting
- Trevena
- Otsuka
- Radiometer
- Abbott Diagnostics
- NIH/NHLBI [R01HL088459-02, K23HL085387-01A2, K12HL1090-01]
- National Center for Advancing Translational Sciences [UL1TR000445]
- Centers for Disease Control
- Roche Diagnostics
- MylanSpecialty L. P.
- Brahms
- Siemens
- Nanosphere
- PDL Biopharma
- AstraZeneca
- Servier
- Merck
- Berlin Chemie
Ask authors/readers for more resources
Background: Dyspnea is the most common symptom in acute heart failure (AHF), yet how to best measure it has not been well defined. Prior studies demonstrate differences in dyspnea improvement across various measurement scales, yet these studies typically enroll patients well after the emergency department (ED) phase of management. Objectives: The aim of this study was to determine predictors of early dyspnea improvement for three different, commonly used dyspnea scales (i.e., five-point absolute Likert scale, 10-cm visual analog scale [VAS], or seven-point relative Likert scale). Methods: This was a post hoc analysis of URGENT Dyspnea, an observational study of 776 patients in 17 countries enrolled within 1 hour of first physician encounter. Inclusion criteria were broad to reflect real-world clinical practice. Prior literature informed the a priori definition of clinically significant dyspnea improvement. Resampling-based multivariable models were created to determine patient characteristics significantly associated with dyspnea improvement. Results: Of the 524 AHF patients, approximately 40% of patients did not report substantial dyspnea improvement within the first 6 hours. Baseline characteristics were similar between those who did or did not improve, although there were differences in history of heart failure, coronary artery disease, and initial systolic blood pressure. For those who did improve, patient characteristics differed across all three scales, with the exception of baseline dyspnea severity for the VAS and five-point Likert scale (c-index ranged from 0.708 to 0.831 for each scale). Conclusions: Predictors of early dyspnea improvement differ from scale to scale, with the exception of baseline dyspnea. Attempts to use one scale to capture the entirety of the dyspnea symptom may be insufficient. (C) 2014 by the Society for Academic Emergency Medicine
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available